Genecast Launches Patient Management Platform to Accelerate Expansion in Digital Health

In recent years, the field of precision oncology has entered a phase of rapid development. Tumor genetic testing based on next-generation sequencing (NGS) technology has become the most dynamic driver within this sector. How to break through in this increasingly competitive landscape is a critical challenge that every company must address.

In the face of new challenges, Genecast leverages advanced technologies such as the internet and big data to integrate online and offline channels and effectively consolidate resources. The company has launched a comprehensive patient management platform offering services including report inquiries, disease management, and an online store, thereby breaking through temporal and spatial constraints and exploring the limitless possibilities of precision medicine.

Long-term postoperative follow-up and tracking management for cancer patients are closely correlated with their survival outcomes. For physicians, organizing and reviewing patient medical records during each follow-up visit consumes considerable effort. Moreover, paper-based and fragmented patient archives and data hinder the subsequent structuring of medical records and impede academic research in the field of oncology treatment.

Through the Genecast Patient Management Platform, physicians can significantly enhance the efficiency of patient management. Physicians can access patients’ historical visit records and medical charts, as well as query various laboratory test indicators in real time. Based on information uploaded by patients, the platform enables data structuring and standardized scale-based assessment, facilitating a comprehensive understanding of patients’ medical histories and supporting more precise clinical judgments and predictions.

The platform also leverages a big data processing system to standardize data storage formats for physicians across different regions, thereby enabling the accumulation of extensive primary data. Building on this foundation, Genecast identifies clinically valuable information from vast medical datasets and employs data mining techniques to address challenges in clinical practice. By empowering data to provide services and assistance to physicians, the company continuously explores new pathways, technologies, and methodologies to better support clinical diagnosis and treatment, efficiently facilitate real-world studies in oncology, and significantly advance scientific research in cancer therapy.

Due to the inconsistent service quality of domestic tumor gene testing institutions, many gene testing companies engage in "one-off transactions," where patients purchase only a single product test. In contrast, Genecast provides patients with comprehensive, end-to-end management and services.

“Addressing a series of pain points that plague both physicians and patients was the original intention behind Genecast’s launch of this platform,” said Du Bo, Co-founder and CEO of Genecast. He emphasized that comprehensive cancer management must extend beyond the hospital setting. Within hospitals, physicians provide professional treatment plans; outside hospitals, the importance of disease management services cannot be overlooked. With this platform, Genecast can create an all-scenario service model for patients, featuring dual-track progress and complementary resources across both in-hospital and out-of-hospital settings.

During medical treatment, in addition to patients’ physical health, mental well-being is also a crucial component. The platform has assembled a professional service team to provide online consultations and address patients’ concerns. Meanwhile, it will regularly deliver high-quality science-based educational content to enhance patients’ scientific understanding of cancer, alleviate psychological distress associated with medical care, and ensure comprehensive support for both physical and mental health.

Cancer treatment is a systematic, arduous, and complex endeavor. With advances in medicine, many cancer patients can now achieve long-term survival while living with the disease; cancer is no longer an "incurable disease" but has become a chronic condition.

Du Bo stated, “Genetic testing is merely one component of the cancer treatment process. We aim to integrate more service modules into our platform in the future, connecting upstream and downstream segments of the industry chain to co-create a closed-loop service system for chronic cancer management. This will facilitate patient access while ensuring the rational allocation of medical resources. Furthermore, the accumulation of service data not only extends healthcare services but also serves as a starting point for scientific research. Ultimately, we can collaborate with pharmaceutical companies to develop new oncology drugs, bringing new hope to patients.”

The journey in oncology treatment is long and arduous, requiring concerted efforts from all sectors of society to comprehensively advance the entire spectrum of cancer prevention, diagnosis, and treatment. Genecast will leverage the technologies and opportunities brought by informatization to fully integrate online systems with offline outpatient resources, connecting doctors, patients, testing institutions, pharmaceutical companies, insurers, and other stakeholders. This aims to achieve the goal of delivering healthcare services that are “empowered by technology and enhanced through innovation.”

If the first half of the competition in the precision oncology diagnostics industry focused on solidifying technology, popularizing knowledge, and capturing market share, the second half will be a comprehensive contest of core strengths, including innovation capability, service quality, and platform power. Who will emerge as the leader? Genecast will provide the answer through its accelerated sprint.